Last reviewed · How we verify
Part B: RPL554
At a glance
| Generic name | Part B: RPL554 |
|---|---|
| Also known as | Part B |
| Sponsor | Verona Pharma plc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler (PHASE2)
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease (PHASE2)
- SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part B: RPL554 CI brief — competitive landscape report
- Part B: RPL554 updates RSS · CI watch RSS
- Verona Pharma plc portfolio CI